Loading...
Compass Ratings
The Alexandria Compass
1,011+ stocks rated across NYSE & NASDAQ. Every stock scored 1–100 blending quantitative financials with qualitative moat, catalyst, and theme analysis — updated daily.
Theme Navigation
Browse Alexandria's ratings universe through its major market themes.
Coverage Universe
1,011 rated stocks organized through the Compass framework.
Updated daily
| Logo | Tier | Category | ||||||
|---|---|---|---|---|---|---|---|---|
K | KNSA | Kiniksa Pharmaceuticals International, plc | 90 | True North | Biotech & Genomics | $5B | +55.5% | 70.9x |
T | TGTX | TG Therapeutics, Inc. | 90 | True North | Biotech & Genomics | $9B | +69.6% | 19.5x |
 | DXCM | DexCom Inc. | 90 | True North | Biotech & Genomics | $27B | +15.0% | 30.6x |
 | ALNY | Alnylam Pharmaceuticals | 90 | True North | Biotech & Genomics | $42B | +96.4% | 78.8x |
H | HALO | Halozyme Therapeutics, Inc. | 90 | True North | Biotech & Genomics | $9B | +42.2% | 27.9x |
 | BEAM | Beam Therapeutics | 90 | True North | Biotech & Genomics | $4B | +324.9% | - |
O | OGN | Organon & Co. | 90 | True North | Biotech & Genomics | $4B | - | 14.5x |
A | ASTH | Astrana Health, Inc. | 89 | True North | Biotech & Genomics | $2B | +55.6% | 80.6x |
 | RXRX | Recursion Pharmaceuticals | 88 | True North | Biotech & Genomics | $4B | +55.0% | - |
A | AGIO | Agios Pharmaceuticals, Inc. | 88 | True North | Biotech & Genomics | $2B | +137.7% | - |
A | ABCL | AbCellera Biologics Inc. | 88 | True North | Biotech & Genomics | $2B | +96.3% | - |
L | LEGN | Legend Biotech Corporation | 87 | True North | Biotech & Genomics | $6B | - | - |
I | IBRX | ImmunityBio, Inc. | 87 | True North | Biotech & Genomics | $10B | +167.6% | - |
 | CRSP | CRISPR Therapeutics | 86 | True North | Biotech & Genomics | $6B | +68.6% | - |
 | ARGX | argenx SE | 86 | True North | Biotech & Genomics | $59B | +62.6% | 41.7x |
T | TARS | Tarsus Pharmaceuticals, Inc. | 85 | True North | Biotech & Genomics | $3B | +106.9% | - |
C | CLOV | Clover Health Investments, Corp. | 85 | True North | Biotech & Genomics | $3B | +62.0% | - |
C | CRNX | Crinetics Pharmaceuticals, Inc. | 84 | True North | Biotech & Genomics | $4B | +2873.4% | - |
S | SUPN | Supernus Pharmaceuticals, Inc. | 84 | True North | Biotech & Genomics | $3B | - | - |
 | LLY | Eli Lilly and Company | 84 | True North | Biotech & Genomics | $750B | +32.0% | 65.0x |
O | OSCR | Oscar Health, Inc. | 83 | True North | Biotech & Genomics | $9B | +52.6% | - |
S | SLN | Silence Therapeutics plc | 82 | True North | Biotech & Genomics | $510M | +197.2% | - |
S | SEPN | Septerna, Inc. | 82 | True North | Biotech & Genomics | $2B | +12011.0% | - |
P | PHAT | Phathom Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $867M | +104.4% | - |
U | URGN | UroGen Pharma Ltd. | 82 | True North | Biotech & Genomics | $2B | +151.6% | - |
C | CRON | Cronos Group Inc. | 82 | True North | Biotech & Genomics | $1B | +40.1% | - |
A | ABUS | Arbutus Biopharma Corporation | 82 | True North | Biotech & Genomics | $962M | +10054.5% | 5.9x |
A | AKTS | Aktis Oncology, Inc. | 82 | True North | Biotech & Genomics | $2B | +123.0% | - |
S | SRTA | Strata Critical Medical, Inc. | 82 | True North | Biotech & Genomics | $448M | +87.4% | - |
B | BIOA | BioAge Labs, Inc. | 82 | True North | Biotech & Genomics | $1B | +91.0% | - |
F | FENC | Fennec Pharmaceuticals Inc. | 82 | True North | Biotech & Genomics | $372M | +72.6% | - |
B | BWAY | BrainsWay Ltd. | 82 | True North | Biotech & Genomics | $610M | +34.6% | 69.0x |
A | AUPH | Aurinia Pharmaceuticals Inc. | 82 | True North | Biotech & Genomics | $2B | +24.4% | 7.2x |
P | PRTC | PureTech Health plc | 82 | True North | Biotech & Genomics | $424M | -38.2% | 9.2x |
P | PRLD | Prelude Therapeutics Incorporated | 82 | True North | Biotech & Genomics | $393M | +116.7% | - |
N | NUVB | Nuvation Bio Inc. | 82 | True North | Biotech & Genomics | $2B | +2598.7% | - |
K | KMTS | Kestra Medical Technologies, Ltd. | 82 | True North | Biotech & Genomics | $2B | +62.7% | - |
C | CRMD | CorMedix Inc. | 82 | True North | Biotech & Genomics | $686M | +226.1% | 4.0x |
Z | ZVRA | Zevra Therapeutics, Inc. | 82 | True North | Biotech & Genomics | $828M | +77.5% | 7.0x |
C | CARL | Carlsmed, Inc. | 82 | True North | Biotech & Genomics | $308M | +58.2% | - |
G | GLPG | Lakefront Biotherapeutics NV | 82 | True North | Biotech & Genomics | $2B | -91.4% | 3.2x |
P | PRTA | Prothena Corporation plc | 82 | True North | Biotech & Genomics | $522M | +1706.4% | - |
S | STAA | STAAR Surgical Company | 82 | True North | Biotech & Genomics | $1B | +119.6% | - |
I | IOVA | Iovance Biotherapeutics, Inc. | 82 | True North | Biotech & Genomics | $2B | +44.8% | - |
O | OABI | OmniAb, Inc. | 82 | True North | Biotech & Genomics | $373M | +247.3% | - |
I | IRWD | Ironwood Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $713M | +158.9% | 7.0x |
A | ANL | Adlai Nortye Ltd. | 82 | True North | Biotech & Genomics | $611M | +178.1% | - |
A | AMN | AMN Healthcare Services, Inc. | 82 | True North | Biotech & Genomics | $1B | +99.9% | - |
C | CDNA | CareDx, Inc. | 82 | True North | Biotech & Genomics | $2B | +39.0% | - |
A | ASND | Ascendis Pharma A/S | 81 | True North | Biotech & Genomics | $18B | +144.3% | 31.8x |